Serum PGLYRP‑1 is a highly discriminatory biomarker for the diagnosis of rheumatoid arthritis

  • Authors:
    • Qing Luo
    • Xue Li
    • Lu Zhang
    • Fangyi Yao
    • Zhen Deng
    • Cheng Qing
    • Rigu Su
    • Jianqing Xu
    • Yang Guo
    • Zikun Huang
    • Junming Li
  • View Affiliations

  • Published online on: November 8, 2018     https://doi.org/10.3892/mmr.2018.9632
  • Pages: 589-594
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Peptidoglycan recognition protein‑1 (PGLYRP‑1) is a part of the innate immune system. It is well‑known that dysregulation of innate immune responses is present in patients with rheumatoid arthritis (RA). However, the role of Pglyrp1/PGLYPR‑1 in RA is poorly understood. Reverse transcription‑quantitative polymerase chain reaction was used to detect the level of Pglyrp1 in peripheral blood mononuclear cells. An ELISA was used to measure the level of PGLYPR‑1 in the serum, and correlation analysis was performed to analyze the association between the level of PGLYPR‑1 in the serum and clinical characteristics. A receiver operating characteristic (ROC) curve was constructed to evaluate the diagnostic value of PGLYPR‑1 in serum. The expression of PGLYPR‑1 in the serum of healthy controls compared with PGLYPR‑1 in the serum from patients with RA was significantly increased compared with patients with systemic lupus erythematosus (SLE). The level of PGLYPR‑1 in serum was correlated with rheumatoid factor and anti‑cyclic citrullinated peptide. ROC curve analysis suggested that PGLYPR‑1 in the serum may have significant value for RA diagnosis. In addition, the risk score based on PGLYPR‑1 in the serum also significantly discriminated the patients with RA from the disease controls (SLE). The present study suggested that increased expression of PGLYPR‑1 in the serum from patients with RA may serve as a potential biomarker for RA diagnosis.
View Figures
View References

Related Articles

Journal Cover

January-2019
Volume 19 Issue 1

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Luo Q, Li X, Zhang L, Yao F, Deng Z, Qing C, Su R, Xu J, Guo Y, Huang Z, Huang Z, et al: Serum PGLYRP‑1 is a highly discriminatory biomarker for the diagnosis of rheumatoid arthritis. Mol Med Rep 19: 589-594, 2019
APA
Luo, Q., Li, X., Zhang, L., Yao, F., Deng, Z., Qing, C. ... Li, J. (2019). Serum PGLYRP‑1 is a highly discriminatory biomarker for the diagnosis of rheumatoid arthritis. Molecular Medicine Reports, 19, 589-594. https://doi.org/10.3892/mmr.2018.9632
MLA
Luo, Q., Li, X., Zhang, L., Yao, F., Deng, Z., Qing, C., Su, R., Xu, J., Guo, Y., Huang, Z., Li, J."Serum PGLYRP‑1 is a highly discriminatory biomarker for the diagnosis of rheumatoid arthritis". Molecular Medicine Reports 19.1 (2019): 589-594.
Chicago
Luo, Q., Li, X., Zhang, L., Yao, F., Deng, Z., Qing, C., Su, R., Xu, J., Guo, Y., Huang, Z., Li, J."Serum PGLYRP‑1 is a highly discriminatory biomarker for the diagnosis of rheumatoid arthritis". Molecular Medicine Reports 19, no. 1 (2019): 589-594. https://doi.org/10.3892/mmr.2018.9632